Isolated Pancreatic Histoplasmosis: An Unusual Suspect of Pancreatic Head Mass in an Immunocompetent Host

Isolated Pancreatic Histoplasmosis: An Unusual Suspect of Pancreatic Head Mass in an Immunocompetent Host


Avin Aggarwal, MD; Shashank Garg, MD

Perm J 2015 Fall; 19(4):e145-e147


Histoplasmosis is endemic to the Mississippi and Ohio River valley regions in the US. It usually affects patients with underlying immunodeficiency but can also be seen in immunocompetent hosts. Although gastrointestinal involvement is common in the setting of disseminated histoplasmosis, isolated gastrointestinal involvement is uncommon. We report a case of isolated pancreatic histoplasmosis in an immunocompetent patient, presenting as painless jaundice and pancreatic head mass.


Histoplasma infection is endemic to the Mississippi and Ohio River valley regions in the US. Although it can involve the gastrointestinal system primarily or as part of disseminated disease, most of such cases are asymptomatic and found on autopsy.1 Only 3% to 12% of these cases manifest clinically, mostly involving the small intestine or colon.2 We present a case of isolated pancreatic histoplasmosis presenting as painless jaundice and pancreatic head mass in an immunocompetent host.

Case Report

A 37-year-old woman was referred to the gastroenterology clinic for incidentally noticed conjunctival icterus of unknown duration and abnormal liver function tests by her primary care physician. She did not report any constitutional or systemic symptoms. Her medical history was significant for Roux-en-Y gastric bypass for obesity and cholecystectomy 4 years earlier. She had been born and brought up in Minnesota and previously worked at a fast food restaurant. She also had a 14-pack-year history of smoking. Family history was unremarkable for malignancy, and social history was unremarkable for recent travel, sick contacts, or any domesticated pets.

At the time of presentation, her vital signs and physical examination were unremarkable except for scleral icterus. Laboratory evaluation revealed elevated liver enzymes (alkaline phosphatase [1137 U/L], alanine aminotransferase [422 U/L], aspartate aminotransferase [223 U/L]), total bilirubin (5.3 mg/dL), and direct bilirubin (4.3 mg/dL). Complete blood count, electrolytes, renal function, serum albumin, lipase, international normalized ratio, and cancer antigen 19-9 were within normal limits. Abdominal ultrasound showed a 5 cm × 4 cm mass in the head of the pancreas with intra- and extrahepatic biliary dilation. A follow-up computed tomography (CT) scan of the abdomen and pelvis with intravenous contrast confirmed a 5 cm × 4.2 cm × 3.7 cm pancreatic head mass with coarse internal calcifications, portal vein compression, and possible local invasion posteriorly into the inferior vena cava and left renal vein (Figure 1). No abdominal lymphadenopathy was noted on CT scan. Magnetic resonance imaging of the abdomen with and without intravenous contrast was performed to assess the vascular invasion seen on the CT scan. It showed a large (4.3 cm × 4.2 cm × 4 cm) mass in the head of the pancreas with numerous foci of amorphous calcification (Figure 2). The mass had numerous large cystic components measuring up to 2.3 cm in size, separated by thick enhancing septae (Figure 3). Common bile duct occlusion and portal vein narrowing from extrinsic compression by the mass were also noted. However, no vascular invasion was seen. Radiologic features were highly suggestive for a mucinous neoplasm, particularly mucinous cystadenocarcinoma. Endoscopic ultrasound was not feasible because of the Roux-en-Y anatomy. Given the high likelihood of malignancy and absence of any metastasis, the pancreatobiliary surgeon decided to proceed with surgical resection.

Intraoperative pathologic examination of frozen section revealed benign necrotizing granulomatous tissue of pancreatic origin, and a Whipple pancreatectomy was performed. Pathologic examination of the resected specimen revealed caseating granulomas and chronic follicular pancreatitis with no dysplastic or neoplastic changes (Figure 4). Fungal yeast forms were seen in the pancreatic and portal lymph node tissue with Gomori methenamine silver stain (Figure 5). However, fungal culture from the resected specimen did not grow any organism. Fungal antibody screen postoperatively was positive for anti-Histoplasma immunoglobulin G antibody (titer 1:16, normal < 1:8). A diagnosis of pancreatic histoplasmosis was made on the basis of pathologic and serologic findings.

Postoperatively, the only recognizable risk factor for histoplasmosis was a history of growing up at a chicken farm. However, there was no history of frequent infections during childhood or presence of immunodeficiency disorders in the family. The patient tested negative for common immunocompromised states including human immunodeficiency virus, tuberculosis, syphilis, hepatitis B, and hepatitis C. She was subsequently started on itraconazole suspension but could not tolerate it. Itraconazole was replaced with voriconazole 200 mg twice a day, but she had an adverse event with this dose of voriconazole (vision change: white color appearing yellow). The adverse effect resolved after the voriconazole dose was reduced to 100 mg twice a day. Her voriconazole level 1 week after initiating the treatment was within normal limits. She was prescribed a 3-month course of voriconazole.

Isolated Pancreatic Histoplasmosis: An Unusual Suspect of Pancreatic Head Mass in an Immunocompetent Host

Isolated Pancreatic Histoplasmosis: An Unusual Suspect of Pancreatic Head Mass in an Immunocompetent Host

Isolated Pancreatic Histoplasmosis: An Unusual Suspect of Pancreatic Head Mass in an Immunocompetent Host

Isolated Pancreatic Histoplasmosis: An Unusual Suspect of Pancreatic Head Mass in an Immunocompetent Host

Isolated Pancreatic Histoplasmosis: An Unusual Suspect of Pancreatic Head Mass in an Immunocompetent Host


To our knowledge, this is the first reported case of symptomatic histoplasmosis localized to the head of the pancreas in an immunocompetent host. Gastrointestinal histoplasmosis has been reported in the literature in immunocompetent hosts. Cappell et al3 and Lamps et al4 reported 77 and 52 cases of gastrointestinal histoplasmosis, respectively. The disease affected immunocompetent patients in 48% to 75% of cases.3,4 The most common sites involved were the small intestine (56% to 79%) and colon (55% to 62%). Pancreatic involvement was reported by Lamps et al4 in 3 patients (6%). However, it is not entirely clear whether the pancreatic involvement was associated with disseminated histoplasmosis or immunosuppression. Similarly, Suh et al5 reported asymptomatic pancreatic enlargement on imaging in 2 cases with acquired immune deficiency syndrome. However, isolated symptomatic pancreatic involvement has not been described before in either immunocompetent or immunocompromised hosts.

There are several unique features in this case. The patient did not have any predisposing factors for histoplasmosis except the history of potential exposure in childhood. Her postoperative evaluation was negative for common immunodeficiency disorders or extrapancreatic disease. It may be prudent to rule out underlying immunodeficiency states and disease dissemination in patients diagnosed with isolated gastrointestinal histoplasmosis.6

Pancreatic involvement by Histoplasma on gastrointestinal imaging bore a remarkable resemblance to pancreatic malignancy. Lee et al7 described a case of disseminated histoplasmosis presenting as a fungating mass in the transverse colon resembling a colon cancer for which the patient underwent a colectomy. Tuberculosis is another granulomatous disease that can mimic malignancy in the head of the pancreas including vascular invasion.8 Endoscopic ultrasound was technically not feasible in our case owing to prior Roux-en-Y gastric bypass. A CT-guided biopsy could have helped in differentiating malignancy from Histoplasma infection. However, the patient did not have any symptoms, signs, or apparent risk factors for Histoplasma or tuberculosis to warrant such testing. Histoplasma has been reported to form caseating or noncaseating granulomas, cystic lesions, and tissue microcalcifications in the gastrointestinal tract.4 All of these pathologic changes were seen in the pancreatic tissue on imaging or pathologic examination of resected specimen.

The diagnosis in this case was based on recognition of the yeast form of Histoplasma in the pancreatic tissue with Gomori methenamine silver stain and subsequent confirmation with positive antibody titer. The urine and serum antigen and the tissue fungal cultures were negative, indicating low fungal burden. This pattern of negative antigen testing and tissue cultures along with a positive serology is more likely to be seen in an immunocompetent state where the immune system will result in a low fungal burden.9,10 Immunocompromised hosts, on the other hand, are more likely to have higher fungal burden with positive antigen tests and culture results and a negative serology.6,11

Itraconazole is considered the treatment of choice in
noncritically ill patients with histoplasmosis.12 However, gastric acid is required for adequate absorption of itraconazole pills and hence could not be used in this case owing to prior Roux-en-Y gastric bypass.13 Itraconazole suspension can be used in this situation, but the patient could not tolerate it.14 Voriconazole was chosen as an alternate, and the patient tolerated it well after the initial dose adjustment with therapeutic drug levels.


Histoplasmosis can present with isolated symptomatic pancreatic involvement in immunocompetent hosts. Tissue sampling should be considered to make a definite diagnosis of malignancy of the head of the pancreas in areas endemic for histoplasmosis or other granulomatous disease, before undertaking surgical resection.

Disclosure Statement

The author(s) have no conflicts of interest to disclose.


Mary Corrado, ELS, provided editorial assistance.

1.    Haggerty CM, Britton MC, Dorman JM, Marzoni FA Jr. Gastrointestinal histoplasmosis in suspected acquired immunodeficiency syndrome. West J Med 1985 Aug;143(2):244-6.
    2.    Wheat LJ, Connolly-Stringfield PA, Baker RL, et al. Disseminated histoplasmosis in the acquired immune deficiency syndrome: clinical findings, diagnosis and treatment, and review of the literature. Medicine (Baltimore) 1990 Nov;69(6):361-74. DOI:
    3.    Cappell MS, Mandell W, Grimes MM, Neu HC. Gastrointestinal histoplasmosis. Dig Dis Sci 1988 Mar;33(3):353-60. DOI:
    4.    Lamps LW, Molina CP, West AB, Haggitt RC, Scott MA. The pathologic spectrum of gastrointestinal and hepatic histoplasmosis. Am J Clin Pathol 2000 Jan;113(1):64-72.
    5.    Suh KN, Anekthananon T, Mariuz PR. Gastrointestinal histoplasmosis in patients with AIDS: case report and review. Clin Infect Dis 2001 Feb 1;32(3):483-91. DOI:
    6.    Kahi CJ, Wheat LJ, Allen SD, Sarosi GA. Gastrointestinal histoplasmosis. Am J Gastroenterol 2005 Jan;100(1):220-31. DOI:
    7.    Lee JT, Dixon MR, Murrell Z, et al. Colonic histoplasmosis presenting as colon cancer in the nonimmunocompromised patient: report of a case and review of the literature. Am Surg 2004 Nov;70(11):959-63.
    8.    Rana SS, Sharma V, Sampath S, Sharma R, Mittal BR, Bhasin DK. Vascular invasion does not discriminate between pancreatic tuberculosis and pancreatic malignancy: a case series. Ann Gastroenterol 2014;27(4):395-8.
    9.    Kauffman CA. Histoplasmosis: a clinical and laboratory update. Clin Microbiol Rev 2007 Jan;20(1):115-32. DOI:
    10.    McKinsey DS, McKinsey JP. Pulmonary histoplasmosis. Semin Respir Crit Care Med 2011 Dec;32(6):735-44. DOI:
    11.    Wheat LJ. Nonculture diagnostic methods for invasive fungal infections. Curr Infect Dis Rep 2007 Nov;9(6):465-71. DOI:
    12.    Wheat J, Sarosi G, McKinsey D, et al. Practice guidelines for the management of patients with histoplasmosis. Infectious Diseases Society of America. Clin Infect Dis 2000 Apr;30(4):688-95. DOI:
    13.    Johnson MD, Hamilton CD, Drew RH, Sanders LL, Pennick GJ, Perfect JR. A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution. J Antimicrob Chemother 2003 Feb;51(2):453-7. DOI:
    14.    Freeman J, Heshmati A, Holland D, Ticehurst R, Lang S. Marked increase in steady-state serum levels achieved with itraconazole oral solution compared with capsule formulation. J Antimicrob Chemother 2007 Oct;60(4):908-9. DOI:


25,000 print readers per quarter, 6900 eTOC readers, and in 2015, 1.4 million page views on TPJ articles in PubMed from a broad international readership


The Permanente Journal (ISSN 1552-5767) is published quarterly by The Permanente Press. The Permanente Journal is available online (ISSN 1552-5775) at


Articles, editorials, letters to the editor, and other material represent the opinion of the authors. Send your comments to

Copyright 2016 The Permanente Journal - Kaiser Permanente. All Rights Reserved.